Consonance Capital Management LP Protagonist Therapeutics, Inc Transaction History

Consonance Capital Management LP

  • $7.28 Million
  • Q3 2022

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$12.95 - $49.69 $44.6 Million - $171 Million
-3,446,874 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$25.57 - $44.88 $18.8 Million - $33.1 Million
737,165 Added 27.2%
3,446,874 $155 Million
Q1 2021

May 17, 2021
SELL
$19.02 - $31.15 $380,400 - $623,000
-20,000 Reduced 0.73%
2,709,709 $70.2 Million
Q4 2020

Feb 16, 2021
BUY
$18.49 - $25.13 $6.66 Million - $9.05 Million
360,000 Added 15.19%
2,729,709 $55 Million
Q3 2020

Nov 16, 2020
BUY
$15.19 - $22.4 $36 Million - $53.1 Million
2,369,709 New
2,369,709 $46.3 Million

Others Institutions Holding PTGX

# of Institutions
212
Shares Held
59.1M
Call Options Held
19K
Put Options Held
107K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Consonance Capital Management LP Portfolio

Follow Consonance Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Consonance Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email